Banner - NPPA Connect

NP/PA Connect
News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|April 11, 2025

Determining Follow-Up Approach in Melanoma Based on GEP Risk Level

Author(s)David Cotter, MD, PhD

An expert discusses whether the 31-gene expression profile (GEP) risk classification would change treatment guidelines and how the patient’s GEP risk level would influence the approach to surveillance and follow-up.

Episodes in this series

EP. 1 Limitations and Challenges in Skin Cancer Staging Systems

EP. 1 Limitations and Challenges in Skin Cancer Staging Systems

EP. 2 Utility of Molecular Testing in Skin Cancer Risk Assessment

EP. 2 Utility of Molecular Testing in Skin Cancer Risk Assessment

EP. 3 Gene Expression Profiling and Other Molecular Tests Utilized for Melanoma and Squamous Cell Carcinoma

EP. 3 Gene Expression Profiling and Other Molecular Tests Utilized for Melanoma and Squamous Cell Carcinoma

EP. 4 Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma

EP. 4 Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma

EP. 5 De-Escalating Treatment Plans With Gene Expression Profiling in an 80-Year-Old Man With SCC

EP. 5 De-Escalating Treatment Plans With Gene Expression Profiling in an 80-Year-Old Man With SCC

EP. 6 Key Takeaways on GEP Testing in Melanoma and SCC

EP. 6 Key Takeaways on GEP Testing in Melanoma and SCC

EP. 7 Determining Follow-Up Approach in Melanoma Based on GEP Risk Level

EP. 7 Determining Follow-Up Approach in Melanoma Based on GEP Risk Level

EP. 8 Transforming Risk Stratification in Melanoma and Squamous Cell Carcinoma

EP. 8 Transforming Risk Stratification in Melanoma and Squamous Cell Carcinoma

Video content above is prompted by the following:

Does the 31-GEP risk classification change your treatment guidelines?
How would you approach surveillance and follow-up with this patient after knowing their GEP risk level?

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

1 expert is featured in this series

Case 1: Choosing Non-Steroidal Topicals for Intertriginous Psoriasis

ByTina Bhutani-Jacques, MD

July 20th 2026

1 expert is featured in this series

The Ongoing Role of Topical Therapy in Plaque Psoriasis Management

ByTina Bhutani-Jacques, MD

July 20th 2026

2 experts are featured in this series

The Safety of Advanced Topical Therapies in Inflammatory Dermatoses

ByPeter Lio, MD,Alexandra K. Golant, MD

July 15th 2026

2 experts are featured in this series

Understanding Corticosteroid-Related Medical-Legal Risks in Inflammatory Dermatoses

ByPeter Lio, MD,Alexandra K. Golant, MD

July 15th 2026

Setting Expectations: Treatment Timelines, Adherence, and Monitoring in Vitiligo

ByNada Elbuluk, MD, MSc, FAAD,Susan Taylor, MD, FAAD

July 14th 2026

Latest CME

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Trending on Dermatology Times

Real-World Study Finds Experienced Dermatologists Outperform AI in Skin Cancer Diagnosis

New Consensus Defines Remission, Disease Activity in Atopic Dermatitis

Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites

Beyond Retinol: Evaluating the Stability, Safety, and Gene-Expression Profile of Bakuchiol Ferulate

AI-Assisted Imaging Tracks Success of Low-Fluence QSRL Laser for Melasma